Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease

Neuroscience

Volumn 290, Issue , 2015, Pages 454-471

  Sconce, M D ^a   Churchill, M J ^a   Moore, C ^a   Meshul, C K ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

7,8 dihydroxyflavone; Collateral sprouting; Motor behavior; Mouse model; MPTP; Parkinson's disease

Indexed keywords

7,8 DIHYDROXYFLAVONE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SUPERIOR CERVICAL GANGLION 10; UNCLASSIFIED DRUG; 6,7-DIHYDROXYFLAVONE; ANTIPARKINSON AGENT; FLAVONE DERIVATIVE; SIGNAL PEPTIDE; STMN2 PROTEIN, MOUSE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FORELIMB; METABOLISM; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; FLAVONES; FORELIMB; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOTOR ACTIVITY; MPTP POISONING; PHOSPHORYLATION; RANDOM ALLOCATION; RECEPTOR, TRKB; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84923063239     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.12.080     Document Type: Article

References (81)

1. Amende I., Kale A., McCue S., Glazier S., Morgan J.P., Hampton T.G. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehabil 2005, 2:20.
2. Ankeny D.P., McTigue D.M., Guan Z., Yan Q., Kinstler O., Stokes B.T., Jakeman L.B. Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp Neurol 2001, 170(1):85-100.
3. Baquet Z.C., Williams D., Brody J., Smeyne R.J. A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 2009, 161(4):1082-1090.
4. Bartus R.T., Weinberg M.S., Samulski R.J. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014, 22(3):487-497.
5. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999, 19(5):1708-1716.
6. Baydyuk M., Nguyen M.T., Xu B. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp Neurol 2011, 228(1):118-125.
7. Benes F.M., Lange N. Two-dimensional versus three-dimensional cell counting: a practical perspective. Trends Neurosci 2001, 24(1):11-17.
8. Benisty S., Boissiere F., Faucheux B., Agid Y., Hirsch E.C. TrkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. Neuroscience 1998, 86(3):813-826.
9. Berardelli A., Rothwell J.C., Thompson P.D., Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001, 124(Pt 11):2131-2146.
10. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20(4):415-455.
11. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 1996, 709(2):319-325.
12. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS J 2012, 279(7):1156-1166.
13. Cabelli R.J., Hohn A., Shatz C.J. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. Science 1995, 267(5204):1662-1666.
14. Carvalho A.L., Caldeira M.V., Santos S.D., Duarte C.B. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008, 153(Suppl. 1):S310-S324.
15. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4(4):299-309.
16. Checkoway H., Powers K., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002, 155(8):732-738.
17. Cheeran B., Talelli P., Mori F., Koch G., Suppa A., Edwards M., Houlden H., Bhatia K., Greenwood R., Rothwell J.C. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008, 586(Pt 23):2575-5717.
18. Chen J., Chua K.W., Chua C.C., Yu H., Pei A., Chua B.H., Hamdy R.C., Xu X., Liu C.F. Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett 2011, 499(3):181-185.
19. Clarke P.G. How inaccurate is the Abercrombie correction factor for cell counts?. Trends Neurosci 1992, 15(6):211-212.
20. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol 1999, 71(3-4):479-500.
21. Cohen-Cory S., Fraser S.E. Effects of brain-derived neurotrophic factor on optic axon branching and remodelling in vivo. Nature 1995, 378(6553):192-196.
22. Devi L., Ohno M. 7, 8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacol 2012, 37(2):434-444.
23. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000, 97(1):99-112.
24. Fritsch B., Reis J., Martinowich K., Schambra H.M., Ji Y., Cohen L.G., Lu B. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 2010, 66(2):198-204.
25. Gallo G., Letourneau P.C. Different contributions of microtubule dynamics and transport to the growth of axons and collateral sprouts. J Neurosci 1999, 19(10):3860-3873.
26. Goldberg N.R., Haack A.K., Lim N.S., Janson O.K., Meshul C.K. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011, 180:256-271.
27. Goldberg N.R., Hampton T., McCue S., Kale A., Meshul C.K. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. J Neurosci Res 2011, 89(10):1698-1706.
28. Goldberg N.R., Fields V., Pflibsen L., Salvatore M.F., Meshul C.K. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis 2012, 45(3):1051-1067.
29. Grenningloh G., Soehrman S., Bondallaz P., Ruchti E., Cadas H. Role of the microtubule destabilizing proteins SCG10 and stathmin in neuronal growth. J Neurobiol 2004, 58(1):60-69.
30. Grewal S.S., York R.D., Stork P.J. Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 1999, 9(5):544-553.
31. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411(6833):86-89.
32. Hallett M., Khoshbin S. A physiological mechanism of bradykinesia. Brain 1980, 103(2):301-314.
33. Hansen J.T., Sakai K., Greenamyre J.T., Moran S. Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat. Brain Res 1995, 670(2):197-204.
34. Hempstead B.L. The many faces of p75NTR. Curr Opin Neurobiol 2002, 12(3):260-267.
35. Holmer H.K., Keyghobadi M., Moore C., Meshul C.K. L-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2005, 136(1):333-341.
36. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1993, 60:140-147.
37. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000, 166(1):127-135.
38. Jang S.W., Liu X., Yepes M., Shepherd K.R., Miller G.W., Liu Y., Wilson W.D., Xiao G., Blanchi B., Sun Y.E., Ye K. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A 2010, 107(6):2687-2692.
39. Kale A., Amende I., Meyer G.P., Crabbe J.C., Hampton T.G. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol Clin Exp Res 2004, 28(12):1839-1848.
40. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10(3):381-391.
41. Khokhlatchev A.V., Canagarajah B., Wilsbacher J., Robinson M., Atkinson M., Goldsmith E., Cobb M.H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 1998, 93(4):605-615.
42. Kleim J.A., Chan S., Pringle E., Schallert K., Procaccio V., Jimenez R., Cramer S.C. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci 2006, 9(6):735-737.
43. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136(Pt 8):2419-2431.
44. Koshimizu H., Kiyosue K., Hara T., Hazama S., Suzuki S., Uegaki K., Nagappan G., Zaitsev E., Hirokawa T., Tatsu Y., Ogura A., Lu B., Kojima M. Multiple functions of precursor BDNF to CNS neurons: negative regulation of neurite growth, spine formation and cell survival. Mol Brain 2009, 13(2):27.
45. Li Y., Yui D., Luikart B.W., McKay R.M., Li Y., Rubenstein J.L., Parada L.F. Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. Proc Natl Acad Sci U S A 2012, 109(38):15491-15496.
46. Liberatore G.T., Finkelstein D.I., Wong J.Y., Horne M.K., Porritt M.J., Donnan G.A., Howells D.W. Sprouting of dopaminergic axons after striatal injury: confirmation by markers not dependent on dopamine metabolism. Exp Neurol 1999, 159(2):565-573.
47. Liu X., Chan C.B., Jang S.W., Pradoldej S., Huang J., He K., Phun L.H., France S., Xiao G., Jia Y., Luo H.R., Ye K. A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J Med Chem 2010, 53(23):8274-8286.
48. Lu B., Nagappan G., Guan X., Nathan P.J., Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013, 14(6):401-416.
49. McAllister A.K., Lo D.C., Katz L.C. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 1995, 15(4):791-803.
50. McNeill T.H., Mori N., Cheng H.W. Differential regulation of the growth-associated proteins, GAP-43 and SCG-10, in response to unilateral cortical ablation in adult rats. Neuroscience 1999, 90(4):1349-1360.
51. Meredith G.E., Totterdell S., Potashkin J.A., Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 2008, 14(SUPPL. 2):S112-S115.
52. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88(1):1-16.
53. Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 2009, 10(12):850-860.
54. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999, 270(1):45-48.
55. Mori N., Morii H. SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. J Neurosci Res 2002, 70(3):264-273.
56. Morii H., Shiraishi-Yamaguchi Y., Mori N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol 2006, 66(10):1101-1114.
57. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011, 10(3):209-219.
58. Nykjaer A., Willnow T.E., Petersen C.M. P75NTR-live or let die. Curr Opin Neurobiol 2005, 15(1):49-57.
59. Obianyo O., Ye K. Novel small molecule activators of the Trk family of receptor tyrosine kinases. Biochim Biophys Acta 1834, 10:2213-2218.
60. Ochs G., Penn R.D., York M., Giess R., Beck M., Tonn J., Haigh J., et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000, 1(3):201-206.
61. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 1999, 10(3):557-561.
62. Pardridge W.M., Wu D., Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998, 15(4):576-582.
63. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013, 14(1):7-23.
64. Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates. Gulf Professional Publishing.
65. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60(8):1234-1240.
66. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38(3-4):277-301.
67. Robinson M.J., Stippec S.A., Goldsmith E., White M.A., Cobb M.H. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 1998, 8(21):1141-1150.
68. Robinson T.E., Castañeda E., Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can J Psychol 1990, 44(2):253-275.
69. Ross G.W., Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001, 18(11):797-806.
70. Shin J.E., Geisler S., DiAntonio A. Dynamic regulation of SCG10 in regenerating axons after injury. Exp Neurol 2014, 252:1-11.
71. Skaper S.D. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 2012, 846:1-12.
72. Smith B.A., Goldberg N.R., Meshul C.K. Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res 2011, 1386:70-80.
73. Smolen A.J., Wright L.L., Cunningham T.J. Neuron numbers in the superior cervical sympathetic ganglion of the rat: a critical comparison of methods for cell counting. J Neurocytol 1983, 12(5):739-750.
74. Thoenen H., Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002, 5(Suppl):1046-1050.
75. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 2011, 1(1):a009316.
76. Touchon J.C., Moore C., Frederickson J., Meshul C.K. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations. Synapse 2004, 51(4):287-298.
77. Tsai T., Klausmeyer A., Conrad R., Gottschling C., Leo M., Faissner A., Wiese S. 7,8-Dihydroxyflavone leads to survival of cultured embryonic motoneurons by activating intracellular signaling pathways. Mol Cell Neurosci 2013, 56:18-28.
78. Xu T., Yu X., Perlik A.J., Tobin W.F., Zweig J.A., Tennant K., Jones T., Zuo Y. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature 2009, 462(7275):915-919.
79. Yang J., Harte-Hargrove L.C., Siao C.J., Marinic T., Clarke R., Priya Q., Jing D., Lafrancois J.J., Bath K.G., Mark W., Ballon D., Lee F.S., Scharfman H.E., Hempstead B.L. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. Cell Rep 2014, 201(7(3)):796-806.
80. Zhang Z., Liu X., Schroeder J.P., Chan C.B., Song M., Yu S.P., Weinshenker D., Ye K. 7,8-Dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2014, 39(3):638-650.
81. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984, 41(8):856-861.